Rep. Julia Letlow Sells Abbott Laboratories (NYSE:ABT) Shares

Representative Julia Letlow (R-Louisiana) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of AstraZeneca (NASDAQ:AZN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

Abbott Laboratories Price Performance

ABT stock traded down $1.51 during trading on Thursday, hitting $123.49. The company had a trading volume of 7,078,996 shares, compared to its average volume of 5,149,897. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average price of $126.10 and a two-hundred day moving average price of $129.10. Abbott Laboratories has a fifty-two week low of $111.02 and a fifty-two week high of $141.23. The company has a market cap of $214.74 billion, a P/E ratio of 15.48, a P/E/G ratio of 2.07 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business’s revenue was up 6.9% on a year-over-year basis. During the same period last year, the business earned $1.21 earnings per share. Equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.0%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Analysts Set New Price Targets

A number of equities analysts have commented on ABT shares. Raymond James Financial boosted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Evercore ISI boosted their target price on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Daiwa Capital Markets increased their price target on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Barclays boosted their price objective on Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Finally, Jefferies Financial Group raised their target price on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $147.42.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the period. State Street Corp raised its position in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after acquiring an additional 689,517 shares during the last quarter. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Geode Capital Management LLC boosted its position in shares of Abbott Laboratories by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Abbott Laboratories during the second quarter worth $3,026,180,000. Institutional investors own 75.18% of the company’s stock.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.